Pharmaceutical Business review

Ipsen acquires Apokyn and Vernalis’s US commercial operations

The subscription by Ipsen for 35.25 million new ordinary shares of GBP0.05 each in the capital of Vernalis, as part of the purchase arrangements, has also been completed.